DR. REDDY'S LABORATORIES-ADR (RDY) Fundamental Analysis & Valuation
NYSE:RDY • US2561352038
Current stock price
13.67 USD
+0.09 (+0.66%)
At close:
13.5637 USD
-0.11 (-0.78%)
After Hours:
This RDY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. RDY Profitability Analysis
1.1 Basic Checks
- In the past year RDY was profitable.
- In the past year RDY had a positive cash flow from operations.
- RDY had positive earnings in each of the past 5 years.
- In the past 5 years RDY always reported a positive cash flow from operatings.
1.2 Ratios
- RDY has a better Return On Assets (10.62%) than 91.62% of its industry peers.
- RDY's Return On Equity of 16.03% is amongst the best of the industry. RDY outperforms 88.48% of its industry peers.
- RDY has a Return On Invested Capital of 13.03%. This is amongst the best in the industry. RDY outperforms 91.62% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for RDY is above the industry average of 13.10%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.62% | ||
| ROE | 16.03% | ||
| ROIC | 13.03% |
ROA(3y)13.25%
ROA(5y)10.88%
ROE(3y)18.65%
ROE(5y)15.68%
ROIC(3y)15.26%
ROIC(5y)13.95%
1.3 Margins
- With an excellent Profit Margin value of 16.82%, RDY belongs to the best of the industry, outperforming 89.01% of the companies in the same industry.
- RDY's Profit Margin has improved in the last couple of years.
- RDY's Operating Margin of 19.62% is amongst the best of the industry. RDY outperforms 87.96% of its industry peers.
- In the last couple of years the Operating Margin of RDY has grown nicely.
- RDY has a better Gross Margin (66.88%) than 74.35% of its industry peers.
- RDY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.62% | ||
| PM (TTM) | 16.82% | ||
| GM | 66.88% |
OM growth 3Y9.42%
OM growth 5Y4.7%
PM growth 3Y19.59%
PM growth 5Y8.42%
GM growth 3Y2.12%
GM growth 5Y0.39%
2. RDY Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so RDY is still creating some value.
- RDY has about the same amout of shares outstanding than it did 1 year ago.
- RDY has more shares outstanding than it did 5 years ago.
- RDY has a worse debt/assets ratio than last year.
2.2 Solvency
- RDY has an Altman-Z score of 5.75. This indicates that RDY is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 5.75, RDY is in the better half of the industry, outperforming 75.92% of the companies in the same industry.
- The Debt to FCF ratio of RDY is 3.17, which is a good value as it means it would take RDY, 3.17 years of fcf income to pay off all of its debts.
- RDY has a Debt to FCF ratio of 3.17. This is amongst the best in the industry. RDY outperforms 90.05% of its industry peers.
- A Debt/Equity ratio of 0.03 indicates that RDY is not too dependend on debt financing.
- RDY has a Debt to Equity ratio (0.03) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 3.17 | ||
| Altman-Z | 5.75 |
ROIC/WACC1.28
WACC10.17%
2.3 Liquidity
- RDY has a Current Ratio of 1.85. This is a normal value and indicates that RDY is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.85, RDY is doing worse than 68.59% of the companies in the same industry.
- A Quick Ratio of 1.35 indicates that RDY should not have too much problems paying its short term obligations.
- With a Quick ratio value of 1.35, RDY is not doing good in the industry: 71.73% of the companies in the same industry are doing better.
- RDY does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.35 |
3. RDY Growth Analysis
3.1 Past
- RDY shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.81%.
- Measured over the past years, RDY shows a very strong growth in Earnings Per Share. The EPS has been growing by 23.62% on average per year.
- RDY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.06%.
- Measured over the past years, RDY shows a quite strong growth in Revenue. The Revenue has been growing by 13.26% on average per year.
EPS 1Y (TTM)3.81%
EPS 3Y33.55%
EPS 5Y23.62%
EPS Q2Q%-14.29%
Revenue 1Y (TTM)11.06%
Revenue growth 3Y14.86%
Revenue growth 5Y13.26%
Sales Q2Q%4.44%
3.2 Future
- RDY is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.17% yearly.
- Based on estimates for the next years, RDY will show a small growth in Revenue. The Revenue will grow by 7.09% on average per year.
EPS Next Y-7.77%
EPS Next 2Y-8.97%
EPS Next 3Y-1.17%
EPS Next 5YN/A
Revenue Next Year6.7%
Revenue Next 2Y5.09%
Revenue Next 3Y6.55%
Revenue Next 5Y7.09%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. RDY Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 19.25, the valuation of RDY can be described as rather expensive.
- Based on the Price/Earnings ratio, RDY is valued cheaper than 84.29% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.42, RDY is valued a bit cheaper.
- Based on the Price/Forward Earnings ratio of 22.92, the valuation of RDY can be described as rather expensive.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of RDY indicates a somewhat cheap valuation: RDY is cheaper than 77.49% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of RDY to the average of the S&P500 Index (22.29), we can say RDY is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.25 | ||
| Fwd PE | 22.92 |
4.2 Price Multiples
- RDY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. RDY is cheaper than 86.39% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, RDY is valued a bit cheaper than the industry average as 77.49% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 58.07 | ||
| EV/EBITDA | 11.5 |
4.3 Compensation for Growth
- The excellent profitability rating of RDY may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.82
EPS Next 2Y-8.97%
EPS Next 3Y-1.17%
5. RDY Dividend Analysis
5.1 Amount
- RDY has a yearly dividend return of 0.60%, which is pretty low.
- Compared to an average industry Dividend Yield of 0.73, RDY pays a better dividend. On top of this RDY pays more dividend than 89.01% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.81, RDY's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.6% |
5.2 History
- The dividend of RDY decreases each year by -19.44%.
- RDY has been paying a dividend for at least 10 years, so it has a reliable track record.
Dividend Growth(5Y)-19.44%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
- RDY pays out 11.54% of its income as dividend. This is a sustainable payout ratio.
- RDY's earnings and Dividend Rate are declining. This means the current dividend is most likely not sustainable.
DP11.54%
EPS Next 2Y-8.97%
EPS Next 3Y-1.17%
RDY Fundamentals: All Metrics, Ratios and Statistics
13.67
+0.09 (+0.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-21 2026-01-21/amc
Earnings (Next)05-12 2026-05-12/amc
Inst Owners52.17%
Inst Owner Change4.02%
Ins Owners1.23%
Ins Owner Change0%
Market Cap11.38B
Revenue(TTM)346.82B
Net Income(TTM)57.72B
Analysts67.56
Price Target14.57 (6.58%)
Short Float %2.49%
Short Ratio6.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.6% |
Yearly Dividend0.08
Dividend Growth(5Y)-19.44%
DP11.54%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.63%
Min EPS beat(2)-8.52%
Max EPS beat(2)-6.74%
EPS beat(4)1
Avg EPS beat(4)-3.93%
Min EPS beat(4)-8.52%
Max EPS beat(4)2.77%
EPS beat(8)4
Avg EPS beat(8)-0.94%
EPS beat(12)8
Avg EPS beat(12)6.66%
EPS beat(16)10
Avg EPS beat(16)7.01%
Revenue beat(2)0
Avg Revenue beat(2)-2.69%
Min Revenue beat(2)-3.88%
Max Revenue beat(2)-1.51%
Revenue beat(4)1
Avg Revenue beat(4)-1.2%
Min Revenue beat(4)-3.88%
Max Revenue beat(4)1%
Revenue beat(8)4
Avg Revenue beat(8)0.25%
Revenue beat(12)7
Avg Revenue beat(12)1.24%
Revenue beat(16)9
Avg Revenue beat(16)1.2%
PT rev (1m)-4.38%
PT rev (3m)-2.35%
EPS NQ rev (1m)0.01%
EPS NQ rev (3m)0.01%
EPS NY rev (1m)-0.79%
EPS NY rev (3m)-1.52%
Revenue NQ rev (1m)-0.43%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)1.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.25 | ||
| Fwd PE | 22.92 | ||
| P/S | 3.13 | ||
| P/FCF | 58.07 | ||
| P/OCF | 18.24 | ||
| P/B | 2.98 | ||
| P/tB | 4.38 | ||
| EV/EBITDA | 11.5 |
EPS(TTM)0.71
EY5.19%
EPS(NY)0.6
Fwd EY4.36%
FCF(TTM)0.24
FCFY1.72%
OCF(TTM)0.75
OCFY5.48%
SpS4.37
BVpS4.59
TBVpS3.12
PEG (NY)N/A
PEG (5Y)0.82
Graham Number8.56235 (-37.36%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.62% | ||
| ROE | 16.03% | ||
| ROCE | 17.14% | ||
| ROIC | 13.03% | ||
| ROICexc | 16.05% | ||
| ROICexgc | 25.11% | ||
| OM | 19.62% | ||
| PM (TTM) | 16.82% | ||
| GM | 66.88% | ||
| FCFM | 5.38% |
ROA(3y)13.25%
ROA(5y)10.88%
ROE(3y)18.65%
ROE(5y)15.68%
ROIC(3y)15.26%
ROIC(5y)13.95%
ROICexc(3y)19.62%
ROICexc(5y)17.62%
ROICexgc(3y)25.36%
ROICexgc(5y)22.59%
ROCE(3y)21.22%
ROCE(5y)19.86%
ROICexgc growth 3Y6.58%
ROICexgc growth 5Y2.58%
ROICexc growth 3Y0.6%
ROICexc growth 5Y-0.12%
OM growth 3Y9.42%
OM growth 5Y4.7%
PM growth 3Y19.59%
PM growth 5Y8.42%
GM growth 3Y2.12%
GM growth 5Y0.39%
F-Score4
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 3.17 | ||
| Debt/EBITDA | 0.13 | ||
| Cap/Depr | 211.61% | ||
| Cap/Sales | 11.76% | ||
| Interest Coverage | 16.55 | ||
| Cash Conversion | 68.09% | ||
| Profit Quality | 32% | ||
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 5.75 |
F-Score4
WACC10.17%
ROIC/WACC1.28
Cap/Depr(3y)179.81%
Cap/Depr(5y)161.03%
Cap/Sales(3y)9.33%
Cap/Sales(5y)8.68%
Profit Quality(3y)47.43%
Profit Quality(5y)60.48%
High Growth Momentum
Growth
EPS 1Y (TTM)3.81%
EPS 3Y33.55%
EPS 5Y23.62%
EPS Q2Q%-14.29%
EPS Next Y-7.77%
EPS Next 2Y-8.97%
EPS Next 3Y-1.17%
EPS Next 5YN/A
Revenue 1Y (TTM)11.06%
Revenue growth 3Y14.86%
Revenue growth 5Y13.26%
Sales Q2Q%4.44%
Revenue Next Year6.7%
Revenue Next 2Y5.09%
Revenue Next 3Y6.55%
Revenue Next 5Y7.09%
EBIT growth 1Y1.53%
EBIT growth 3Y25.68%
EBIT growth 5Y18.58%
EBIT Next Year11.24%
EBIT Next 3Y7.07%
EBIT Next 5Y9.87%
FCF growth 1Y-62.42%
FCF growth 3Y9.92%
FCF growth 5Y-12.7%
OCF growth 1Y-18.43%
OCF growth 3Y18.21%
OCF growth 5Y9.24%
DR. REDDY'S LABORATORIES-ADR / RDY Fundamental Analysis FAQ
What is the ChartMill fundamental rating of DR. REDDY'S LABORATORIES-ADR (RDY) stock?
ChartMill assigns a fundamental rating of 6 / 10 to RDY.
What is the valuation status for RDY stock?
ChartMill assigns a valuation rating of 5 / 10 to DR. REDDY'S LABORATORIES-ADR (RDY). This can be considered as Fairly Valued.
How profitable is DR. REDDY'S LABORATORIES-ADR (RDY) stock?
DR. REDDY'S LABORATORIES-ADR (RDY) has a profitability rating of 8 / 10.
What are the PE and PB ratios of DR. REDDY'S LABORATORIES-ADR (RDY) stock?
The Price/Earnings (PE) ratio for DR. REDDY'S LABORATORIES-ADR (RDY) is 19.25 and the Price/Book (PB) ratio is 2.98.
How financially healthy is DR. REDDY'S LABORATORIES-ADR?
The financial health rating of DR. REDDY'S LABORATORIES-ADR (RDY) is 6 / 10.